Shape-changing enzyme suggests how small doses of anti-HIV drug might treat Alzheimer’s

An approved anti-HIV drug latches to the enzyme already responsible for about 80 percent of the cholesterol elimination from the human brain, report scientists. Obtained with a cutting-edge atom-substitution technology called hydrogen-deuterium exchange, the molecular roadmap shows how small amounts of the drug can kick the enzyme, called CYP46A1, into higher gear.